GlassScriptPhysician profile
Tamera S Spangler
NPI 1316387079
$3,827.77
in general payments reported to CMS, 2019-2025
42 companies · $791 in 2025
The $791 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,365 · 2020: $243 · 2022: $215 · 2023: $438 · 2024: $776 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,005.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $453.87 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $317.18 | 2019-2025 | Vraylar |
| Glaxosmithkline, LLC. | $272.14 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $235.26 | 2019-2025 | Ozempic, Wegovy |
| Pfizer INC. | $227.34 | 2019-2025 | |
| Astellas Pharma US INC | $212.42 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $199.51 | 2019-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.31 | 2019-2024 | Trulance, Xifaxan |
| Amgen INC. | $186.91 | 2019-2024 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.61 | 2019-2025 | Ofev, Jardiance |
| Otsuka America Pharmaceutical, INC. | $158.79 | 2023-2025 | Rexulti, Abilify Maintena |
| Antares Pharma, INC. | $152.32 | 2022-2024 | Xyosted |
| Xeris Pharmaceuticals, INC. | $112.10 | 2022-2023 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $97.28 | 2019-2023 | Spravato |
| Sanofi-Aventis U.S. LLC | $77.89 | 2019-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamera Spangler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.